Drug Trial Radar · NCT04677439
Flumatinib in CML-CP Patients With Ph+ Post Imatinib Failure
Last checked: Nov 19, 2026Latest source record: Mar 16, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
200
Planned (sponsor's estimate)
Start
Jan 1, 2021
Primary completion
May 30, 2023
Study completion Dec 30, 2023
Sponsor
- Lead sponsor
- Shenzhen Second People's HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Hainan General Hospital; Sanya Central Hospital; First Affiliated Hospital of Shantou University Medical College; Peking University Shenzhen Hospital; Dongguan People's Hospital
- First posted
- Dec 21, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to explore the efficacy and safety of flumatinib in chronic phase of chronic myeloid leukemia (CML-CP) patients With Ph+ post imatinib failure.
Conditions
- Flumatinib
- Chronic Myeloid Leukemia, Chronic Phase
- Imatinib
Interventions
FlumatinibDrug
600 mg of Flumatinib orally daily for 24 months
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of patients who achieve and maintain MMR at 12 months using RQ-PCR test.Time frame: 12 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Second People's Hospital of Shenzhen
Shenzhen, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.